Complex generic product sponsors seem to have a better handle on the purpose of the US Food and Drug Administration's pre-ANDA meeting program but still are struggling with the requirements.
Data through the first three quarters of fiscal year 2019 suggest that sponsors are seeing fewer meeting requests denied because...








